Therapy options in irritable bowel syndrome

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 12, 2010, Pages 1402-1411

  Enck, Paul ^a   Junne, Florian ^a   Klosterhalfen, Sibylle ^a,b   Zipfel, Stephan ^a   Martens, Ute ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

dietary therapy; drug therapy; irritable bowel syndrome; meta analysis; probiotics; psychotherapy; randomized controlled trials; therapy

Indexed keywords

ALOSETRON; ANTIDEPRESSANT AGENT; CISAPRIDE; DOMPERIDONE; PEPPERMINT OIL; PROBIOTIC AGENT; RENZAPRIDE; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ALGORITHM; BRAN; CLINICAL DECISION MAKING; COGNITIVE THERAPY; COLON MOTILITY; DIET THERAPY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; IRRITABLE COLON; PRIORITY JOURNAL; PSYCHODYNAMICS; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RELAXATION TRAINING; REVIEW;

ALGORITHMS; ANTIDEPRESSIVE AGENTS; DIETARY FIBER; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; ODDS RATIO; PATIENT SELECTION; PLANT OILS; PROBIOTICS; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 78349249028     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283405a17     Document Type: Review

References (53)

1. Camilleri M. Drug development and IBS drugs: experience from the past, current challenges, and proposal forthe future. Curr Opin Pharmacol2008; 8:671-676.
2. Ford AC,Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect offibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337:a2313.
3. Ford AC,Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58:367-378.
4. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104:1831-1843.
5. Lesbros-Pantoflickova D, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20:1253-1269.
6. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; CD003460.
7. Zijdenbos IL, De Wit NJ, Van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev 2009; CD006442.
8. Moayyedi P, Ford AC,Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59:325-332.
9. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol2009; 9:15.
10. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol2009; 15:1548-1553.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
12. McKay DL, Blumberg JB. A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L.). Phytother Res 2006; 20:619-633.
13. Von Arnim U, Peitz U,Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102:1268-1275.
14. Ammon HP, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle. Phytomedicine 2006; 13 (Suppl 5):67-74. (Pubitemid 44809870)
15. Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102:1276-1283.
16. Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M. Comorbidity in irritable bowel syndrome. Am J Gastroenterol 2007; 102:2767-2776.
17. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse reactions to antidepressants. Br J Psychiatry2009; 195:202-210.
18. Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6:277-295.
19. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55:1095-1103.
20. Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, et al. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010; 8:42-48.
21. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16:547-553.
22. Khalif IL, Quigley EM, Makarchuk PA, Golovenko OV, Podmarenkova LF, Dzhanayev YA. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). J Gastrointestin Liver Dis 2009; 18:17-22.
23. Bertrand PP, Bertrand RL. Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci 2010; 153:47-57.
24. Manabe N, Wong BS, Camilleri M. New-generation 5-HT(4) receptor agonists: potential fortreatment of gastrointestinal motility disorders. Expert Opin Investig Drugs 2010; 19:765-775.
25. Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6:545-555.
26. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-weektrials. Clin Ther2008; 30:884-901.
27. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; CD003960.
28. Update in: Cochrane Database Syst Rev 2007;(4): CD003960.
29. Lackner JM, Jaccard J, Krasner SS, Katz LA, Gudleski GD, Blanchard EB. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology 2007; 133:433-444.
30. Toner BB. Cognitive-behavioral treatment of irritable bowel syndrome. CNS Spectr 2005; 10:883-890.
31. Creed F, Guthrie E. Psychological treatments of the irritable bowel syndrome: a review. Gut 1989; 30:1601-1609.
32. Hefner J, Rilk A, Herbert BM, Zipfel S, Enck P, Martens U. Hypnotherapy for irritable bowel syndrome-a systematic review. Z Gastroenterol 2009; 47:1153-1159.
33. Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007; CD005110.
34. Wilson S, Maddison T, Roberts L, Greenfield S, Singh S; Birmingham IBS Research Group. Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006; 24:769-780.
35. Lahmann C, Röhricht F, Sauer N, Noll-Hussong M, Ronel J, Henrich G, et al. Functional relaxation ascomplementarytherapy in irritable bowel syndrome: a randomized, controlled clinical trial. JAltern Complement Med 2010; 16:47-52.
36. Shinozaki M, Kanazawa M, Kano M, Endo Y, Nakaya N, Hongo M, Fukudo S. Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial. Appl Psychophysiol Biofeedback 2010; 35:189-198.
37. Morcos A, Dinan T, Quigley EM. Irritable bowel syndrome: role offood in pathogenesis and management. J Dig Dis 2009; 10:237-246.
38. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-2661.
39. Haller D, Antoine JM, Bengmark S, Enck P, Rijkers GT, Lenoir-Wijnkoop I. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J Nutr 2010; 140:690S-697S.
40. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104:1033-1049.
41. Enck P, Zimmermann K, Menke G, Müller-Lissner S, Martens U, Klosterhalfen S. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome-a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008; 20:1103-1109.
42. Kajander K, Krogius-Kurikka L, Rinttila T, Karjalainen H, Palva A, Korpela R. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther2007; 26:463-473. (Pubitemid 47063154)
43. Lee KJ,Tack J. Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22:493-498.
44. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology2006; 130:1480-1491.
45. Jellema P, Van der Windt DA, Schellevis FG, Van der Horst HE. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther 2009; 30:695-706.
46. Lea R, Hopkins V, Hastleton J, Houghton LA, Whorwell PJ. Diagnostic criteria for irritable bowel syndrome: utility and applicability in clinical practice. Digestion 2004; 70:210-213.
47. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108-2131. (Pubitemid 35408332)
48. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56:1770-1798.
49. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-370.
50. Gøtzsche PC, Hróbjartsson A, Maric K,Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. JAMA 2007; 298:430-437.
51. Ford AC, Guyatt GH, Talley NJ, Moayyedi P. Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. Am J Gastroenterol 2010; 105:280-288.
52. Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, Berman B. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; CD005111.
53. Shi J,Tong Y, Shen JG, Li HX. Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review. World J Gastroenterol 2008; 14:454-462.